HM Payson & Co. reduced its holdings in Bristol-Myers Squibb Company (NYSE:BMY) by 0.8% in the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 89,748 shares of the biopharmaceutical company’s stock after selling 700 shares during the quarter. HM Payson & Co.’s holdings in Bristol-Myers Squibb were worth $5,001,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Blue Chip Partners Inc. increased its position in Bristol-Myers Squibb by 0.8% in the 1st quarter. Blue Chip Partners Inc. now owns 2,141 shares of the biopharmaceutical company’s stock valued at $116,000 after acquiring an additional 17 shares during the period. Keel Point LLC increased its position in Bristol-Myers Squibb by 0.3% in the 1st quarter. Keel Point LLC now owns 6,286 shares of the biopharmaceutical company’s stock valued at $342,000 after acquiring an additional 18 shares during the period. Staley Capital Advisers Inc. increased its position in Bristol-Myers Squibb by 0.3% in the 1st quarter. Staley Capital Advisers Inc. now owns 6,962 shares of the biopharmaceutical company’s stock valued at $379,000 after acquiring an additional 24 shares during the period. Shayne & CO. LLC increased its position in Bristol-Myers Squibb by 0.6% in the 2nd quarter. Shayne & CO. LLC now owns 4,041 shares of the biopharmaceutical company’s stock valued at $225,000 after acquiring an additional 24 shares during the period. Finally, Greenleaf Trust increased its position in Bristol-Myers Squibb by 0.4% in the 2nd quarter. Greenleaf Trust now owns 9,608 shares of the biopharmaceutical company’s stock valued at $535,000 after acquiring an additional 39 shares during the period. Hedge funds and other institutional investors own 68.93% of the company’s stock.

A number of equities research analysts have recently commented on BMY shares. Credit Suisse Group reaffirmed a “hold” rating and issued a $61.00 price objective (up from $58.00) on shares of Bristol-Myers Squibb in a research note on Friday, October 27th. Cowen and Company reaffirmed a “hold” rating and issued a $65.00 price objective on shares of Bristol-Myers Squibb in a research note on Tuesday, September 19th. Jefferies Group LLC upped their price objective on shares of Bristol-Myers Squibb from $66.00 to $72.00 and gave the company a “buy” rating in a research note on Monday, September 11th. Piper Jaffray Companies reaffirmed a “hold” rating and issued a $60.00 price objective on shares of Bristol-Myers Squibb in a research note on Friday, October 27th. Finally, Leerink Swann upped their price objective on shares of Bristol-Myers Squibb from $61.00 to $72.00 and gave the company an “outperform” rating in a research note on Monday, October 23rd. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and twelve have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $64.93.

ILLEGAL ACTIVITY WARNING: “HM Payson & Co. Sells 700 Shares of Bristol-Myers Squibb Company (BMY)” was originally reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this piece on another domain, it was illegally stolen and republished in violation of US and international copyright legislation. The original version of this piece can be accessed at https://theolympiareport.com/2017/11/02/hm-payson-co-sells-700-shares-of-bristol-myers-squibb-company-bmy.html.

In other news, SVP Joseph C. Caldarella sold 9,340 shares of the business’s stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total transaction of $560,400.00. Following the sale, the senior vice president now owns 46,297 shares in the company, valued at approximately $2,777,820. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 0.23% of the company’s stock.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.77 by ($0.02). The company had revenue of $5.25 billion for the quarter, compared to analysts’ expectations of $5.20 billion. Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. The firm’s revenue for the quarter was up 6.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.77 earnings per share.

The firm also recently announced a quarterly dividend, which was paid on Wednesday, November 1st. Stockholders of record on Friday, October 6th were issued a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a dividend yield of 2.53%. The ex-dividend date was Thursday, October 5th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 61.42%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with Analyst Ratings Network's FREE daily email newsletter.